PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7495746-7 1995 Cross-linking of TCR-CD3 together with CD4, CD8 or LFA-1 markedly inhibited glucocorticoid-induced death and the inhibition was canceled by FK506. Tacrolimus 140-145 CD8a molecule Homo sapiens 44-47 7495746-0 1995 Cross-linking of the TCR-CD3 complex with CD4, CD8 or LFA-1 induces an anti-apoptotic signal in thymocytes: the signal is canceled by FK506. Tacrolimus 134-139 CD8a molecule Homo sapiens 47-50 7495746-5 1995 On the other hand, upon cross-linking TCR-CD3 together with CD4, CD8 or LFA-1, FK506 markedly enhanced DNA fragmentation and cytolysis. Tacrolimus 79-84 CD8a molecule Homo sapiens 65-68 34607938-9 2021 In vitro treatment of healthy CD4+ and CD8+ T cells with tacrolimus abrogated the proliferation and cytokine (INF-gamma, IL-2, and TNF-alpha) secretion associated with the type 1 inflammatory phenotype observed in pre- and post-PTx rejectors. Tacrolimus 57-67 CD8a molecule Homo sapiens 39-42 7528255-7 1994 After the induction of FK506, the number of CD8 positive cells decreased and cardiac rejection was successfully resolved. Tacrolimus 23-28 CD8a molecule Homo sapiens 44-47 33936035-7 2021 Through gene set enrichment analysis, we found that this subpopulation is similar to virus-specific CD8+ T cells and T cells that mediate acute rejection in patients using tacrolimus and belatacept, a selective costimulation blocker. Tacrolimus 172-182 CD8a molecule Homo sapiens 100-103 34619854-11 2021 Tacrolimus inhibited the proliferation of CD8+T cells when IL-2 concentration was 20.0,200.0 and 2 000.0 U/ml (P<0.05). Tacrolimus 0-10 CD8a molecule Homo sapiens 42-45 34619854-12 2021 The expression of perforin in CD8+T cells of SAA patients treated with tacrolimus was significantly lower than that in blank control group and IL-2 group ((2.25+-0.76)%, (6.70+-0.82)% vs (9.10+-1.90)%,all P<0.05). Tacrolimus 71-81 CD8a molecule Homo sapiens 30-33 34619854-13 2021 The level of IFN-gamma in CD8+T cells group after applying tacrolimus was significantly lower than that in the blank control group (P<0.05). Tacrolimus 59-69 CD8a molecule Homo sapiens 26-29 34619854-15 2021 The expression of perforin in CD8+T cells in tacrolimus group was significantly lower than that in SAA group ((18. Tacrolimus 45-55 CD8a molecule Homo sapiens 30-33 34841735-5 2021 The increased percentage of senescent CD8+ CD57+ T lineages and less responsive T cell receptor (TCR) pathway in the FK506 group indicate better graft acceptance. Tacrolimus 117-122 CD8a molecule Homo sapiens 38-41 30472069-6 2019 We determined that tacrolimus profoundly suppressed CD4 and CD8 T cell proliferation and significantly suppressed Th1 and Th17 responses, as demonstrated by a reduced frequency of IFN-gamma, IL-2, and IL-17 producing CD4 T cells and reduced frequencies of IFN-gamma and IL-2 producing CD8 T cells. Tacrolimus 19-29 CD8a molecule Homo sapiens 60-63 30633591-5 2019 Results: It is found that percentages of CD3+, CD3+CD4+ and CD3+CD8+ T cells in FK506 group are lowered compared to the control group but they are elevated in FK506 + MMF group. Tacrolimus 80-85 CD8a molecule Homo sapiens 64-67 30633591-5 2019 Results: It is found that percentages of CD3+, CD3+CD4+ and CD3+CD8+ T cells in FK506 group are lowered compared to the control group but they are elevated in FK506 + MMF group. Tacrolimus 159-164 CD8a molecule Homo sapiens 64-67 30472069-6 2019 We determined that tacrolimus profoundly suppressed CD4 and CD8 T cell proliferation and significantly suppressed Th1 and Th17 responses, as demonstrated by a reduced frequency of IFN-gamma, IL-2, and IL-17 producing CD4 T cells and reduced frequencies of IFN-gamma and IL-2 producing CD8 T cells. Tacrolimus 19-29 CD8a molecule Homo sapiens 285-288 30228949-7 2018 While both rapamycin and the calcineurin inhibitor tacrolimus elongated the survival of OVA-expressing skin grafts, and inhibited short-term antigen-specific CD8+ T cell responses, rapamycin but not tacrolimus permitted the statistically significant infiltration of CD8+ effector memory T cells into UV-induced SCC lesions. Tacrolimus 51-61 CD8a molecule Homo sapiens 158-161 30228949-7 2018 While both rapamycin and the calcineurin inhibitor tacrolimus elongated the survival of OVA-expressing skin grafts, and inhibited short-term antigen-specific CD8+ T cell responses, rapamycin but not tacrolimus permitted the statistically significant infiltration of CD8+ effector memory T cells into UV-induced SCC lesions. Tacrolimus 51-61 CD8a molecule Homo sapiens 266-269 19737140-9 2009 In vitro, methylprednisolone and gabexate mesilate had no effect and cyclosporin A and tacrolimus only a moderate effect on production of granzyme b by CD8(+) T cells. Tacrolimus 87-97 CD8a molecule Homo sapiens 152-155 23743668-10 2013 Tacrolimus 10 ng/mL reduced the production of IL-2 in CD4 and CD8 T cells by 28.9% and 45.4% (P < 0.05). Tacrolimus 0-10 CD8a molecule Homo sapiens 62-65 23743668-12 2013 This effect on tacrolimus pharmacodynamics was associated with ABCB1 3435C>T SNP in renal transplant patients: verapamil reduced the percentage of IL-2-producing CD4 and CD8 T cells by 14% and 22% in patients with the CC genotype (P < 0.05) but not in patients with the TT genotype. Tacrolimus 15-25 CD8a molecule Homo sapiens 173-176 23743668-13 2013 Moreover, the ratio of tacrolimus C0 over the percent of IL-2-producing CD8 T cells in CC genotype patients was significantly higher compared with TT genotype patients (P < 0.05), showing a smaller pharmacodynamic effect in CC genotype patients. Tacrolimus 23-33 CD8a molecule Homo sapiens 72-75 22141281-6 2011 Tacrolimus treatment significantly attenuated TREC content within cultured CD4+CD8- cells from PM/DMpatients (p < 0.05), but total cell counts were not significantly changed. Tacrolimus 0-10 CD8a molecule Homo sapiens 79-82 20624462-8 2010 Additional immunosuppression with tacrolimus or deoxyspergualin after transplantation delayed post-transplant proliferation of effector memory CD8(+) T cells but did not promote chimerism. Tacrolimus 34-44 CD8a molecule Homo sapiens 143-146 24704664-12 2014 Tubular epithelial cell-induced CD8 degranulation and CD8-mediated TEC lysis were preferentially inhibited by tacrolimus and prednisolone, and not by everolimus. Tacrolimus 110-120 CD8a molecule Homo sapiens 32-35 24704664-12 2014 Tubular epithelial cell-induced CD8 degranulation and CD8-mediated TEC lysis were preferentially inhibited by tacrolimus and prednisolone, and not by everolimus. Tacrolimus 110-120 CD8a molecule Homo sapiens 54-57 18845086-0 2008 [Regulatory function of tacrolimus and CsA on CD4/CD8 T lymphocyte subgroups and costimulators on them in allo-liver recipients]. Tacrolimus 24-34 CD8a molecule Homo sapiens 50-53 19233271-11 2009 On the other hand, in vitro assays showed that cyclosporine (5.0 ug/mL) and tacrolimus (100 ng/mL) diminished the percentages of CD8+CD28- cells, with no significant effect on natural T regulatory cells. Tacrolimus 76-86 CD8a molecule Homo sapiens 129-132 19162189-10 2009 Immunohistochemistry revealed a high number of CD4+ cells and high CD4/CD8 ratio in grafts pre-treated with tacrolimus. Tacrolimus 108-118 CD8a molecule Homo sapiens 71-74 18845086-1 2008 AIM: To explore the regulatory function of FK506 and CsA on CD4/CD8 T lymphocyte subgroups and co-stimulators on them. Tacrolimus 43-48 CD8a molecule Homo sapiens 64-67 18845086-6 2008 Between two treatment group, the expression of CD4(+)T cells and the expression of CD28 and ICOS on CD8(+)T cells in CsA-treated group were much higher than those in FK506-treated group (P<0.05), and there was no significant difference between two treatment groups in other indexes. Tacrolimus 166-171 CD8a molecule Homo sapiens 100-103 14550820-7 2003 RESULTS: CsA and FK 506 reduced the presence graft-infiltrating leukocytes (CD4, CD8, CD11a, CD18) in the PVS of intra- and epicardial arteries when compared with control animals. Tacrolimus 17-23 CD8a molecule Homo sapiens 81-84 17223872-6 2007 RESULTS: CD3+, CD4+ and CD8+ lymphocytes, and eosinophil and neutrophil granulocytes were significantly reduced in post-treatment tacrolimus specimens, while CD1a+ cells and mast cells were not. Tacrolimus 130-140 CD8a molecule Homo sapiens 24-27 15899924-2 2005 Immunosuppressive drugs, such as FK506 and cyclosporin A, block the priming of alloreactive CD4 T(h) cells and the subsequent induction of allospecific CD8 cytotoxic effector T cells and inhibit allograft rejection. Tacrolimus 33-38 CD8a molecule Homo sapiens 152-155 14966413-8 2004 FK506 reduced the expansion of donor CD8+ and, to a lesser extent, CD4+ T cells in the spleen and inhibited donor anti-host T-cell proliferative and cytotoxic responses. Tacrolimus 0-5 CD8a molecule Homo sapiens 37-40 15480330-11 2004 Interestingly, tacrolimus therapy was also associated with a reduction of CD8 + T cells expressing the T H 1 cytokine IFN-gamma. Tacrolimus 15-25 CD8a molecule Homo sapiens 74-77 11237798-0 2001 CD8+ cytotoxic lymphocyte responses against cytomegalovirus after liver transplantation: correlation with time from transplant to receipt of tacrolimus. Tacrolimus 141-151 CD8a molecule Homo sapiens 0-3 12142035-3 2002 The calcineurin inhibitor FK506 at 1nM inhibited the development of thymocytes to either lineage, but 0.3nM FK506 significantly switched the development from the CD4 cell fate to the CD8 cell fate. Tacrolimus 108-113 CD8a molecule Homo sapiens 183-186 11477316-0 2001 Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Tacrolimus 37-47 CD8a molecule Homo sapiens 131-134 11477316-0 2001 Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Tacrolimus 37-47 CD8a molecule Homo sapiens 142-145 11237798-4 2001 There was an inverse correlation among levels of the calcineurin inhibitor, tacrolimus, and ppUL83 CD8(+) CTL frequencies (r=-.31; P=.005), which is consistent with the presence of a large proportion (70%) of activated (CD38(+)) ppUL83 CD8(+) CTL within the population of HLA class I tetramer-positive cells. Tacrolimus 76-86 CD8a molecule Homo sapiens 99-102 10729997-8 2000 These results suggest that, compared with CsA, tacrolimus administered prophylactically induces more CD8+CD57+ lymphocytes when acute GVHD occurs and accelerates the recovery from acute GVHD more rapidly. Tacrolimus 47-57 CD8a molecule Homo sapiens 101-104 10729997-4 2000 The percentage of CD8+CD57+ cells in the patients receiving tacrolimus and developing acute graft-versus-host disease (GVHD) (grade I, 20.1% +/- 10.6%; grade II-IV, 13.2% +/- 6.3%) was significantly higher than in the patients receiving CsA and developing acute GVHD (grade I, 10.7% +/- 5.2%; grade II-IV, 7.7% +/- 4.0%) (grade I, P = .0036; grade II-IV, P = .0255). Tacrolimus 60-70 CD8a molecule Homo sapiens 18-21 10729997-5 2000 The absolute number of CD8+CD57+ cells in the patients with grade II-IV acute GVHD was also significantly higher in the tacrolimus group compared with the CsA group. Tacrolimus 120-130 CD8a molecule Homo sapiens 23-26 10789681-0 2000 Involvement of FK506-sensitive and insensitive granule exocytosis pathways in perforin-dependent target cell lysis mediated by a CD8+ CTL clone. Tacrolimus 15-20 CD8a molecule Homo sapiens 129-132 10789681-1 2000 The release of granzyme A and B through granule exocytosis by CD8+ CTL clone OE4 upon T cell receptor (TCR) activation was blocked by FK506 in a dose-dependent manner (IC50 = 3 nM), whereas a significant granzyme release was still detectable even in the presence of excess FK506. Tacrolimus 134-139 CD8a molecule Homo sapiens 62-65 10789681-1 2000 The release of granzyme A and B through granule exocytosis by CD8+ CTL clone OE4 upon T cell receptor (TCR) activation was blocked by FK506 in a dose-dependent manner (IC50 = 3 nM), whereas a significant granzyme release was still detectable even in the presence of excess FK506. Tacrolimus 273-278 CD8a molecule Homo sapiens 62-65 9642110-5 1998 FK506 inhibited the CD8 downregulation in both cell types. Tacrolimus 0-5 CD8a molecule Homo sapiens 20-23 9371682-5 1997 Increased thymic apoptosis resulted in the disappearance of CD4+CD8+ thymocytes after FK506/dexamethasone injection. Tacrolimus 86-91 CD8a molecule Homo sapiens 64-67